資料來源：https://www.reuters.com/article/us-abbvie-trials-idUSKBN17L2X7

AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer and triple negative breast cancer.

Veliparib belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

(Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza)